Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) EBIT Margin: 2009-2025

Historic EBIT Margin for Aytu Biopharma (AYTU) over the last 17 years, with Sep 2025 value amounting to -10.83%.

  • Aytu Biopharma's EBIT Margin fell 522.00% to -10.83% in Q3 2025 from the same period last year, while for Sep 2025 it was -13.19%, marking a year-over-year decrease of 968.00%. This contributed to the annual value of -11.79% for FY2025, which is 845.00% down from last year.
  • According to the latest figures from Q3 2025, Aytu Biopharma's EBIT Margin is -10.83%, which was up 78.50% from -50.37% recorded in Q2 2025.
  • Aytu Biopharma's EBIT Margin's 5-year high stood at 16.78% during Q4 2023, with a 5-year trough of -220.76% in Q1 2022.
  • In the last 3 years, Aytu Biopharma's EBIT Margin had a median value of -10.45% in 2024 and averaged -10.94%.
  • In the last 5 years, Aytu Biopharma's EBIT Margin crashed by 13,159bps in 2021 and then spiked by 18,311bps in 2023.
  • Aytu Biopharma's EBIT Margin (Quarterly) stood at -48.84% in 2021, then soared by 2,270bps to -26.13% in 2022, then spiked by 4,292bps to 16.78% in 2023, then crashed by 2,723bps to -10.45% in 2024, then crashed by 522bps to -10.83% in 2025.
  • Its EBIT Margin was -10.83% in Q3 2025, compared to -50.37% in Q2 2025 and 13.12% in Q1 2025.